FOLD News and Press, Amicus Therapeutics Inc. From 09/03/20

CRANBURY, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences in September: Citi’s 15 th Annual BioP...

Image source: The Motley Fool. Amicus Therapeutics Inc   (NASDAQ: FOLD) Q2 2020 Earnings Call Aug 10, 2020 , 8:30 a.m. ET Operator Continue reading

Amicus Therapeutics, Inc. (FOLD) Q2 2020 Earnings Conference Call August 10, 2020 08:30 AM ET Company Participants Andrew Faughnan - Director of Investor Relations John Crowley - Chairman & Chief Executive Officer Bradley Campbell - President & Chief Operating Officer D...

The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with their 2020 Q2 earnings Read more ...

Amicus Therapeutics (NASDAQ: FOLD ) : Q2 GAAP EPS of -$0.20 beats by $0.07 . More news on: Amicus Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Galafold 2Q2020 Revenue of $62.4 Million, On-Track to Achieve 2020 Revenue Guidance of  $250M-$260M AT-GAA Phase 3 PROPEL Study Readout and Rolling BLA Submission to U.S. FDA on Schedule Advancing Industry-Leading Rare Disease Gene Therapy Portfolio Path to...

CRANBURY, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 11, 2020 at 9:00 a.m. E.T. A live aud...

CRANBURY, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, August 10, 2020 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2020. The...

Applied DNA reports positive preclinical results for COVID-19 vaccine Applied DNA Sciences Inc. ( APDN ) announced that its COVID-19 vaccine candidate has yielded robust antibody and T-cell responses even at very low doses of linear DNA. The company is collaborating with Takis Biotech for ...

Amicus Therapeutics (NASDAQ: FOLD ) inks an agreement with Hayfin Capital Management for a $400M credit facility at 6.5% above LIBOR subject to a 1% floor. More news on: Amicus Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...